GTBP 2.18 (-3.11%)
US36254L2097BiotechnologyBiotechnology

GT Biopharma (GTBP) Stock Highlights

2.18 | -3.11%
2024-09-19 07:11:33
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Statistics

Range Today
2.13 2.29
Volume Today 13.3K
Range 1 Year
0.21 10.66
Volume 1 Year 95.5M
Range 3 Year
0.18 10.66
Volume 3 Year 204.11M
Range 10 Year
0.18 47.6
Volume 10 Year 346.07M

Highlights

Market Capitalization 4.87M (micro)
Floating Shares 1.79M
Current Price 2.18
Price To Earnings -0.27
Price To Book 0.88
Earnings Per Share -7.76
Payout Ratio 0%

Performance

Latest -3.11%
1 Month -3.11%
3 Months -25.6%
6 Months -52.81%
1 Year +707.41%
3 Years -71.32%
5 Years -28.76%
10 Years -92.18%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.